NeuroJust – 3-Month Case Study (September – November)

1. Month-by-Month Performance

September

• Ad Spend: $1,367.31
  
• Leads: 65
  
• CPL: $21
  
• Evaluations: 8
  
• CPE: $170.91
  
• Conversions: 3 patients
  
• Eval → Patient Conversion: 37.5%
  

Although September had lower volume, it delivered strong patient quality.

October

• Ad Spend: $1,514
  
• Leads: 58
  
• CPL: $26
  
• Evaluations: 18
  
• CPE: $84.11
  
• Conversions: 8 patients
  
• Eval → Patient Conversion: 44.4%
  

October delivered the strongest conversion results with excellent efficiency.

November

• Ad Spend: $1,919
  
• Leads: 90
  
• CPL: $21.32
  
• Evaluations: 15
  
• CPE: $127.93
  
• Upcoming Evaluations: Several still scheduled
  (Even with 5 fewer operating days)
  

2. Total 3-Month Performance (Sept → Nov)

• Total Ad Spend: $4,800.31
  
• Total Leads: 213
  
• Total Evaluations: 41
  
• Upcoming Evaluations: 11
  
• Completed Evaluations: 3
  

Total Patient Conversions

• 3 (September)
  
• 8 (October + November) = 11 total patients converted
  

3. Funnel Conversion Rates

• Lead → Eval Conversion: 19.2%
  
• Eval → Patient Conversion (completed evals only): 36.67%
  

4. Revenue & ROAS

LTV: $6,000 per patient

Total Revenue: 11 patients × $6,000 = $66,000

ROAS: $66,000 ÷ $4,800.31 = 13.74× ROAS
(1,374% return on ad spend)

5. Summary

Across three months, NeuroJust achieved:

• Ad spend: $4,800.31

• 213 leads generated
  
• 41 evaluations (11 still upcoming)
  
• 11 patient conversions
  
• $66,000 in revenue
  
• 13.74× ROAS
  
• Strong funnel metrics:
  
  • 19.2% lead → eval
    
  • 36.67% eval → patient
    

September delivered high-quality conversions, while October produced the strongest overall performance with the highest number of new patients. November maintained efficiency despite fewer days of operation and generated several upcoming evaluations that are still expected to convert.

NeuroJust is positioned for sustained growth with a strong pipeline and exceptional profitability.

6. Next Steps & Growth Plan

NeuroJust’s performance over the last three months has built a strong foundation for continued expansion. With consistent patient conversions, a healthy evaluation pipeline, and highly profitable ROAS, the next logical phase is structured scaling.

December: Launching the Second Location

Beginning in December, we will begin running and optimizing campaigns for NeuroJust’s second clinic location.
This expansion will allow us to:

• Double lead flow across two service areas
  
• Split TMS and Ketamine strategies by location for higher efficiency
  
• Strengthen local presence and improve treatment accessibility
  
• Replicate the proven funnel that is currently generating 13.74× ROAS
  

The second location serves as the first major step toward regional dominance.

Q1 2026: Multiple New Locations Coming

Due to the excellent results, predictable conversions, and strong revenue generation, NeuroJust is planning further expansion in Q1 2026, with additional clinic openings underway.

This expansion will allow us to:

• Deploy multi-location campaigns with shared audience intelligence
  
• Scale patient volume with controlled CPL and CPE
  
• Optimize each location’s treatment mix (TMS, Psychiatric services)
  
• Build a replicable, scalable marketing infrastructure
  

The performance achieved so far shows NeuroJust is ready to move from “growth” to “multi-location scaling.”

Scaling Strategy for 2025–2026

As NeuroJust expands, our focus will be:

1. Doubling Evaluation Volume

• Increasing budgets strategically while maintaining efficiency
  
• Introducing new funnels for TMS, and Psychiatric evaluations
  
• Strengthening the follow-up workflow to maximize show rates
  

2. Strengthening Patient Conversion

• Insurance-first qualification
  
• Optimizing PA workflows
  
• Increasing same-week evaluation availability
  

3. Building Multi-Location Dominance

• Custom campaigns per ZIP code cluster
  
• Localized creative and messaging
  
• Cross-location retargeting systems
  

4. Scaling Revenue Predictably

• Maintaining ROAS above 10×
  
• Keeping CPE stable across locations
  
• Forecasting staffing needs (psychiatrists, TMS techs, care coordinators)
  

Summary

With a proven model delivering 11 patients, $66,000 in revenue, and 13.74× ROAS, NeuroJust is now positioned to enter its next growth phase—scaling from a single-location clinic to a multi-location regional provider.

December marks the beginning, and Q1 2026 will be a key milestone as new locations launch and expansion accelerates.